Yang Xue-Wei, Li Shan-Shan, Su Yan-Hua, Sun Jia-Yue, Gao Yu-Juan
Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin 150000, Heilongjiang Province, China.
Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin 150000, Heilongjiang Province, China.E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Oct;32(5):1313-1316. doi: 10.19746/j.cnki.issn.1009-2137.2024.05.002.
To analyze the clinical characteristics and prognosis of patients with co-mutation of gene and gene, so as to facilitate clinicians to formulate more accurate individualized treatment plans for patients.
A total of 43 acute myeloid leukemia (AML) patients with double mutations and domain mutation admitted to the First Affiliated Hospital of Harbin Medical University from January 2017 to April 2022 were included, and the clinical characteristics and prognosis of patients with gene mutation among them were compared and analyzed.
The median age of patients with gene mutation was 48.0 years, which was significantly lower than 57.0 years of patients without gene mutation ( < 0.05). However, there were no significant differences in sex, white blood cell count, hemoglobin concentration, platelet count, immunophenotype, bone marrow and peripheral blood blast cell ratio and complete remission rate between the two groups ( >0.05). The median overall survival and event-free survival time of patients with gene mutation were not reached, while those of patients without gene mutation were 14.8 and 8.1 months, respectively (both < 0.05).
The median age of patients with gene mutation is lower than that of patients without gene mutation. gene mutation further prolongs the survival time of AML patients with double mutations and domain mutation.
分析基因与基因共突变患者的临床特征及预后，以便于临床医生为患者制定更精准的个体化治疗方案。
纳入2017年1月至2022年4月哈尔滨医科大学附属第一医院收治的43例具有双突变和结构域突变的急性髓系白血病（AML）患者，比较并分析其中基因突变患者的临床特征及预后。
基因突变患者的中位年龄为48.0岁，显著低于无基因突变患者的57.0岁（<0.05）。然而，两组在性别、白细胞计数、血红蛋白浓度、血小板计数、免疫表型、骨髓及外周血原始细胞比例和完全缓解率方面均无显著差异（>0.05）。基因突变患者的中位总生存期和无事件生存期未达到，而无基因突变患者的分别为14.8个月和8.1个月（均<0.05）。
基因突变患者的中位年龄低于无基因突变患者。基因突变进一步延长了具有双突变和结构域突变的AML患者的生存时间。
